MARKET

XNCR

XNCR

Xencor
NASDAQ
11.89
+0.48
+4.21%
After Hours: 11.89 0 0.00% 16:10 06/09 EDT
OPEN
11.61
PREV CLOSE
11.41
HIGH
12.04
LOW
11.57
VOLUME
1.01M
TURNOVER
--
52 WEEK HIGH
18.69
52 WEEK LOW
6.92
MARKET CAP
881.54M
P/E (TTM)
-5.1732
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at XNCR last week (0601-0605)?
Weekly Report · 1d ago
Acting FDA head vows to block political interference, Endpoint News says
TipRanks · 5d ago
FDA issues draft guidance to help accelerated cell, gene therapies for patients
TipRanks · 06/02 14:03
Weekly Report: what happened at XNCR last week (0525-0529)?
Weekly Report · 06/01 09:05
Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial
Seeking Alpha · 05/30 17:46
Weekly Report: what happened at XNCR last week (0518-0522)?
Weekly Report · 05/25 09:05
MindWalk publishes Discovery-to-Clinic presentation factsheet
PUBT · 05/18 12:36
Weekly Report: what happened at XNCR last week (0511-0515)?
Weekly Report · 05/18 09:05
More
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Webull offers Xencor Inc stock information, including NASDAQ: XNCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XNCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XNCR stock methods without spending real money on the virtual paper trading platform.